Ayeska Callender
Adult Health · Newark, NJNPI 1215507785
Payments from drug & device makers
Across 135 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$533
- United Therapeutics Corporation$499
- Astellas Pharma US Inc$383
- Takeda Pharmaceuticals U.S.A., Inc.$327
- Mylan Specialty L.p.$230
- Merck$230
- plus $811 from 17 others
What the payments were for
- Food & beverage$2,86395%
- Education$1505%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $533 |
| United Therapeutics Corporation | 24 | $499 |
| Astellas Pharma US Inc | 15 | $383 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $327 |
| Mylan Specialty L.p. | 8 | $230 |
| Merck | 7 | $230 |
| Actelion Pharmaceuticals US, Inc. | 12 | $193 |
| Boehringer Ingelheim | 8 | $116 |
| Viiv Healthcare Company | 6 | $97 |
| AstraZeneca | 5 | $81 |
| Sanofi | 4 | $58 |
| Bayer | 4 | $56 |
| Abiomed | 1 | $42 |
| Atricure, Inc. | 1 | $30 |
| Viatris Specialty LLC | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Harmony Biosciences LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,013 in reported general payments places this provider in the 85th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 24 | $8,423 |
| Tacrolimus | 91 | $6,947 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,639 |
| Valganciclovir Hcl | 15 | $1,732 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,628 |
| Dapsone | 31 | $1,348 |
| Mycophenolate Mofetil | 25 | $1,327 |
| Azithromycin | 59 | $690 |
| Pantoprazole Sodium | 82 | $483 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 64 | $429 |
| Prednisone | 160 | $424 |
| Pravastatin Sodium | 42 | $409 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $369 |
| Alendronate Sodium | 30 | $262 |
| Carvedilol | 17 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $533 | $5,63912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Newark
- Scott StewartNewark$10K
- Maria RamirezNewark$7K
- Angela McCall BrownNewark$7K
- June HalperHackensack$458K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.